Rilpivirine (Edurant®)

Assessment Status Rapid Review Complete
Drug Rilpivirine
Brand Edurant®
Indication In combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml.
Assessment Process
Rapid review commissioned 14/12/2011
Rapid review completed 06/01/2012
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended